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Abstract 
Background: K13 propeller (k13) polymorphism are useful molecular markers for tracking the emergence and spread 
of artemisinin resistance in Plasmodium falciparum. Polymorphisms are reported from Cambodia with rapid invasion 
of the population and almost near fixation in south East Asia. The study describes single nucleotide polymorphisms in 
Kelch protein propeller domain of P. falciparum associated with artemisinin resistance from Southern Pakistan.
Methods: Two hundred and forty-nine samples were collected from patients with microscopy confirmed P. falcipa-
rum malaria attending Aga Khan University Hospital during September 2015-April 2018. DNA was isolated using the 
whole blood protocol for the QIAmp DNA Blood Kit. The k13 propeller gene (k13) was amplified using nested PCR. 
Double-strand sequencing of PCR products was performed using Sanger sequencing methodology. Sequences were 
analysed with MEGA 6 and Bio edit software to identify specific SNP combinations.
Results: All isolates analysed for k13 propeller allele were observed as wild-type in samples collected post imple-
mentation of ACT in Pakistan. C580Y, A675V, Y493H and R539T variants associated with reduced susceptibility to 
artemisinin-based combination therapy (ACT) were not found. Low frequency of M476I and C469Y polymorphisms 
was found, which is significantly associated with artemisinin resistance.
Conclusion: Low frequencies of both nonsynonymous and synonymous polymorphisms were observed in P. falci-
parum isolates circulating in Southern Pakistan. The absence of known molecular markers of artemisinin resistance 
in this region is favourable for anti-malarial efficacy of ACT. Surveillance of anti-malarial drug resistance to detect its 
emergence and spread need to be strengthened in Pakistan.
Keywords: Artemisinin, Plasmodium falciparum, Pakistan, Drug resistance
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ 
zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Drug resistance to anti-malarial is a major public health 
problem in malaria endemic countries, even with reduc-
tion in malaria cases and deaths, it is estimated that 229 
million cases of malaria occurred worldwide in 2019 
leading to an estimated—409,000 deaths globally [1]. 
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mortality over 15  years (2000–2015), a total of 413,533 
confirmed malaria cases were reported in 2019 out of 
which 87,169 were confirmed Plasmodium falciparum 
in Pakistan [1]. According to the World Health Organi-
zation (WHO), first-line recommended treatment in 
Pakistan for uncomplicated P. falciparum malaria infec-
tions was artesunate plus sulfadoxine-pyrimethamine 
(AS + SP) due to high prevalence of chloroquine resist-
ance in P. falciparum isolates [2].
This treatment policy has been recently revised to 
artemether-lumefantrine + primaquine for uncompli-
cated P. falciparum malaria [1]. Rapid emergence and 
spread of artemisinin resistance in P. falciparum is how-
ever of great concern. Plasmodium falciparum resistance 
to artemisinin is firmly established in five countries in the 
Greater Mekong Sub region: Cambodia, Laos, Thailand, 
Myanmar, and Vietnam [3, 4].
Spread of artemisinin resistance in P. falciparum 
requires effective molecular surveillance of artemisinin 
resistance. Recently, polymorphisms in the k-13 propel-
ler gene in P. falciparum have been found to be a useful 
marker for artemisinin resistance. Single nucleotide poly-
morphisms (SNPs) in the k13 region are associated with 
delayed parasite clearance, both in vivo and in vitro and 
significantly associated day 3 positive parasitaemia [3, 4]. 
More than 200 mutations in k13 gene, including 108 non-
synonymous variants have been reported globally [5].
Polymorphisms at nineteen loci in k13 propeller gene 
(k13) reported from southeast Asia became a molecu-
lar signature of artemisinin resistance [6, 7]. Variants 
at position F446I, N485Y, Y493H, R539T, P574L and 
C580Y were responsible for delayed parasite clearance 
in patients treated with artemisinin-based combination 
therapy (ACT) and are, therefore, important determi-
nants of artemisinin resistance [8, 9]. Further, genome 
wide association studies (GWAS) confirmed that these 
mutations demonstrate independent emergence at multi-
ple geographical locations thus needs large-scale molecu-
lar surveillance [10, 11].
k13 SNPs associated with artemisinin resistance from 
the China-Myanmar border, India, Bangladesh and some 
African countries have been reported [4, 10, 12–14]. Var-
ious non-synonymous variants associated with delayed 
parasite clearance have been reported from Africa in low 
frequencies [5]. A578S is the most common non-synon-
ymous mutation found in parasites from five countries 
in sub-Saharan Africa, Western Kenya and Equatorial 
Guinea [15]. A578S mutation was present with a preva-
lence of > 1% and located close to the C580Y mutation 
[10].
There is a paucity of data on molecular markers of arte-
misinin resistance in P. falciparum from Pakistan. There-
fore, rapid molecular surveillance of parasite populations 
for artemisnin resistance can help to inform the selec-
tion of drugs by control programmes. As an adjunct to 
in  vivo drug efficacy studies, large-scale molecular sur-
veillance of drug resistance markers is needed urgently in 
Pakistan. The aim of this study was to assess the genetic 
polymorphisms in k13 propeller of P. falciparum associ-
ated with artemisinin resistance from Southern Pakistan. 
Molecular data collected from malaria-endemic regions 
will help in understanding the presence of variants in k13 
propeller gene associated with delayed parasite clearance 
in P. falciparum. The study reports k13 propeller SNPs 
and Pfmdr1 gene copy number variation in P. falcipa-
rum malaria cases from Southern Pakistan.
Methods
Study setting, participants and ethics
The study was conducted between June 2015–2018 at the 
Aga Khan University Hospital, a tertiary hospital located 
in central Karachi, and its established chain of primary 
health care and diagnostic service centers located in 
Sindh and Baluchistan provinces, Pakistan. In the study 
area, malaria transmission peaks during and after the 
monsoon season that lasts from June to October. Patients 
with microscopy confirmed P. falciparum mono-infec-
tion were eligible for enrolment irrespective of age, gen-
der and disease severity.
The study was conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice [16]. 
Informed consent was obtained from all participants or 
in case of children from their parents/legal guardians. 
The study was approved by the ethical review committee 
of Aga Khan University Hospital, Karachi, Pakistan.
Blood collection and microscopy
Two ml of intravenous blood were collected in an EDTA 
tube from all patients suspected of malaria referred to 
the laboratory for investigation of malaria infection. For 
screening purposes, a thick blood film was prepared and 
analysed using Leishman stain according to routine lab-
oratory practice. In case of a positive screening result, a 
thick and thin Giemsa-stained blood film was prepared 
for confirmation of the presence of malaria parasites and 
species identification. For all patients with confirmed 
P. falciparum mono-infection the parasite density was 
assessed by counting asexual parasites against 200 white 
blood cells (WBC) on the thick film and quantified 
(parasites/µl) by assuming an average of 8000 WBC per 
μl blood [17]. All blood slides were examined by experi-
enced microscopist at the clinical laboratory of Aga Khan 
University Hospital. For quality control, 10% of the blood 
slides were re-examined by an independent microscopist 
unaware of the initial result.
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The remaining blood was transferred to cryovials 
and kept frozen at −80ºC until used for DNA extrac-
tion. A brief epidemiological and demographic history 
was also collected from each participant using a struc-
tured questionnaire.
DNA extraction and PCR genotyping of k13 propeller 
domain
DNA was extracted using Qiamp DNA mini Kits (Qia-
gen, USA) from 200  µl of whole blood as per manu-
facturer’s instructions. Extracted DNA was stored at 
– 20 °C until amplified by PCR.
The k13 propeller domain was amplified by nested 
PCR described elsewhere [4]. Briefly, using the fol-
lowing primers: for the primary PCR (kelch-out-f 
5′CGG AGT G ACC AAA TCT GGG A-3′ and kelch-out-r 
5′GGG AAT CTG GTG GTA ACA GC-3′) and the nested 
PCR (kelch-in1-r 5′GCC TTG TTG AAA GAA GCA 
GA-3′, kelch-in1-f 5′-GCC AAG CTG CCA TTC ATT 
TG-3′ kelch-in-f_5′CGC CAG CAT TGT TGA CTA AT-3′ 
and kelch-in-r 5′GCG GAA GTA GTA GCG AGA AT-3′). 
The size of nested PCR products were 1312 and 849 bp 
corresponding to nucleotide 101–1412 and 1279–2127 
(representing codons 427–709) of PF3D7_1343700. 
k13 propeller domain representing codons 427–709 
included variants related to delayed parasite clear-
ance. PCR products were resolved on 2% agarose gels 
(Amresco, Solon, OH) visualized under UV transil-
lumination  (GelDoc®, Biorad, Hercules, CA, USA) 
(Additional file 1).
Secondary PCR products were purified by ExoSAP-
IT (Affymetrix, Santa Clara, CA, USA) and sequenced 
commercially (Macrogen Inc. Seoul, Korea). The prim-
ers for sequencing were same with those of nested 
PCR.
Pfmdr1 gene copy number variation polymorphism 
was determined using real time PCR (ABI  Prism® 7500) 
as previously described [18]. All samples were run in 
duplicates. The clones, 3D7 and K1 were used as single 
copy calibrators and FCB and Dd2 represented multiple 
copy controls. Pfmdr1 copy numbers were calculated 
using a comparative threshold method (ΔΔCt method).
Statistical analyses
Data were entered, validated and analysed using 
SPSS version 16.0. Molecular Evolutionary Genet-
ics Analysis (MEGA) software version 10 was used to 
analyse the sequences using the 3D7 clone sequence 
(PF3D7_1343700 K13) obtained from NCBI database 
as a reference [19] (Additional file  2). SNP propor-
tions were calculated as the number carrying a certain 
resistant allele divided by the number of samples with 
positive PCR outcome.
Results
A total of 1016 patients with malaria were included 
in this study and two hundred and forty-nine were 
microscopy and PCR confirmed for P. falciparum 
mono-infection, remaining were confirmed as P. vivax 
malaria. Patients from all age groups were infected and 
there was no significant difference among pediatrics 
and adult population. The demographic of the patients 
are presented in Table 1. A total of 241 (97%) sequence 
from k13 propeller  PCR  products were obtained. K13 
propeller gene sequences from study isolates were com-
pared with the reference 3D7 strain (PF3D7_1343700) 
retrieved from Gene bank.
Substitutions at positions Y493H, F446I, R539T, 
R561H, P574L and C580Y were not detected in this 
study isolates. M476I was observed in was observed 
in 3 isolates none of the patients had history of travel 
and recovered from malaria post treatment. C469Y was 
observed in one isolate. Nonsynonymous novel muta-
tions at positions T508N and S577L were observed in 
12 (5%) and 13 (5%) isolates, respectively. These novel 
mutations were associated with delayed parasite clear-
ance or treatment failures in the study subject. Low 
frequency of K189T mutation outside k13 propeller 
region was reported in this study (Table  2). No  k13 
propeller  validated variants were detected at positions 
F446I, Y493H, G538V, R539T, P553L, R561H, V568G, 
P574L, C580Y and A675V in this study. Double muta-
tions were not observed in any isolate, all the samples 
tested showed single k13 variant. The most common 
k13 haplotype based on globally reported 19 SNPs was 
wild type in this study. The wild type haplotype defined 
Table 1 Demographic characteristics of enrolled patients
a Number of patients are presented with proportions in brackets
b Parasite densities were available form 216 patients. Median data are presented 








 ≤ 5 years 68 [6.69%] 46 [5.99%] 22 [8.8%]
 6–15 years 137 [13.4%] 97 [12.6%] 40 [16.0%]
 > 15 years 811 [79.8%] 624 [81.3%] 187 [75.1%]
Sexa
 Male 705 [69.3%] 529 [68.9%] 176 [70.6%]
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as FGNSCAFLYGPEPACVEAA at amino acid posi-
tions 446, 450, 458, 459, 469, 481, 483, 492, 519, 533, 
556, 574, 578, 580, 581, 668, 675 and 676. Amplification 
in pfmdr1 gene copy number was not observed in the 
study isolates.
Discussion
This study reports survey of k13 propeller polymor-
phisms in  P. falciparum  from southern Pakistan major-
ity of samples were from metropolitan of Karachi with a 
population of more than 16 million. Candidate variants 
in the k13 gene N458Y, F466I, Y493H, R539T, P574L 
and C580Y, which were associated with delayed para-
site clearance and prolonged ex vivo parasite survival in 
Southeast Asia were not observed [4, 8].
K189T is a common mutation observed in upstream 
region of k13 gene. It has not been associated with arte-
misnin resistant clinical phenotype [14, 20]. Low propor-
tion of K189T was found in this study. Low frequencies 
of K189T has also been reported from Bangladesh and 
China-Myanmar border in comparison to a higher 
prevalence in Africa. In addition, K189T mutation was 
reported from India with a comparatively higher fre-
quency, however no correlation with artemisnin resist-
ance was observed [21].
Low frequency of M476I with no clinical evidence of 
artemisnin resistance was observed in this study. M476I 
variant has been associated with artemisinin tolerance 
in  vitro in the Tanzanian parasite population and is a 
validated marker of artemisinin resistance. This finding 
is alarming and suggest that larger scale monitoring may 
be urgently required. These variants in k13 gene have also 
previously been reported from southern Myanmar, South 
Vietnam, Bangladesh and India [14, 22]. C469Y is known 
to be associated with artemisinin tolerance from China-
Myanmar border and Uganda is reported in one isolate in 
this study [3, 23].
Variants associated with artemisnin resistance in South 
East Asia were not detected in Africa suggesting inde-
pendent origin of mutation in different regions [10, 24, 
25]. V566I and A578S are most notable of seven unique 
nonsynonymous variants reported from sub-Saharan 
Africa which were not observed in Southeast Asia [26]. 
A578S has been commonly reported from Africa, India 
and Bangladesh with no clinical evidence of artemisinin 
resistance [5, 21].
F466I, Y493H, R539T, P574L and C580Y variants have 
reached intermediate to fixation status in South East Asia 
and China where currently artemisinin resistance is con-
fined. These variants confer resistance in an artemisinin-
resistant parasite line selected in the laboratory and are 
associated with delayed parasite clearance in clinical 
isolates [4, 27]. F446I which is highly prevalent in China-
Myanmar and Northern Myanmar and has been associ-
ated with prolonged parasite clearance recently was not 
reported in this study [28, 29]. C580Y is highly prevalent 
in Cambodia, Thailand and Myanmar. The frequency 
of the C580Y allele increased significantly in two west-
ern provinces of Cambodia and it became near fixation 
in these areas. Association of N458Y with artemisinin 
resistance was inconsistently reported from the Thai- 
Myanmar border region. Y493H and C580Yvariants 
reportedly originating from Cambodia have subsequently 
spread throughout Vietnam [6].
Single nucleotide polymorphism in k13 conferring 
drug resistance have emerged independently and differ 
regionally [4, 10]. In recent study it has been noted that 
validated and candidate k13 mutation may not confer 
Table 2 Frequency of k13 propeller variants observed in this study
NS nonsynonymous, S synonymous, [–] variants of unknown significance or not reported
k13 variants that are either validated or are associated/candidates for ART resistance are shown
Variant types Single nucleotide 
polymorphism
Base substitution Variant Frequency Wild type Status Variant type
Wild type – – – 241 (1) – WT
K189T c.566A > C AAA > ACA 1 [0.004] 240 [0.99] – NS
C469Y c.1407C > G TGC > TGG 1 [0.004] 240 [0.99] Candidate NS
M476I c.1428G > T ATG > ATT 3 [0.01] 238 [ 0.98] Validated NS
F483I c.1447T > A TTT > ATT 9 [0.04] 232 [0.96] – NS
S485N c.1454G > A AGT > AAT 7 [0.03] 234 [0.97] – NS
F491F c.1473F > F TTC > TTT 52 [0.22] 189 [0.78] – S
L492L c.1476A > G TTA > TTG 2 [0.01] 239 [0.99] – S
F506V c.1516 T > G TTT > GTT 8 [0.03] 232 [0.96] – NS
T508N c.1523C > A ACT > AAT 12 [0.05] 229 [0.95] – NS
S577L c.1730S > L TCA > TTA 13 [0.05] 228 [0.95] – NS
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artemisinin resistance in isolation but would act in pres-
ence of multiple variant which were noted in African and 
Southeast Asian parasite populations [27, 30].
In this study, low frequency of k13 propeller muta-
tions were observed and no previously validated arte-
misinin resistance variant reported from South East Asia 
were found. A majority of isolates in this study carried 
wild-type k13 propeller gene corresponds to haplotype 
FGNSCAFLYGPEPA-CVEAA [31]. Synonymous and 
nonsynonymous substitutions of unclear phenotype were 
identified. Recent studies from Pakistan also reported a 
lack of k13 variants associated with artemisinin resist-
ance. Both studies, however reported synonymous and 
non- synonymous with no or limited association with 
artemisnin resistance consistent with current findings 
[32, 33]. These results are encouraging and suggest that 
artemisinin resistance is not yet established in Southern 
Pakistan. However, presence of low frequency of M476I 
and evolving variants is however alarming. This study 
shows there may be regional variation in mutation profile 
and therefore it is important that consistent and regular 
molecular surveillance monitoring is conducted through-
out Pakistan.
Although critical SNPs associated with artemisinin 
resistance in SE Asia were not detected in this study and 
concur with African studies which report different muta-
tion [24, 25]. Novel  k13 propeller  coding substitutions 
T508N and S57L were reported in this study. The phe-
notypes of these coding polymorphisms remain unclear 
and will require further characterization to better char-
acterize the clinical impact on artemisinin resistance in 
Southern Pakistan.
This study confirms that recently revised treatment 
option from AT + SP to AL for uncomplicated P. falci-
parum malaria should be an effective regimen as pfmdr1 
gene amplifications were not observed. Pfmdr1 gene 
copy number amplification has been associated with 
an increased risk for treatment failure after mefloquine 
monotherapy and artesunate-mefloquine combination 
therapy [18]. Presence of single copy pfmdr 1 gene is 
consistent with previously reported studies from Paki-
stan [2]. The low prevalence of pfmdr1 amplifications 
observed in this study suggests that both artesunate-
mefloquine and artemether-lumefantrine combination 
would be efficacious in Southern Pakistan.
One of the limitation of the present study was absence 
of availability of coordinated clinical follow up, patient 
outcomes and molecular data to provide better under-
standing of the biological and clinical impact of these 
unique genotypes. Complementing these studies with 
ongoing, large-scale molecular epidemiologic sur-
veillance will enhance ability to monitor artemisinin 
resistance in Pakistan. Integration of these efforts in the 
national malaria control programme may help forestall 
the spread of resistance and enhance the global durability 
of artemisinin therapies.
The absence of known molecular markers of arte-
misinin resistance in this region is favourable for the 
anti-malarial efficacy of ACT. However, presence of 
M476I in low frequency is matter of concern in Paki-
stan. It is difficult to predict how soon resistance vari-
ants may appear in absence of wide scale molecular 
surveillance. Validated data on k13 mutation are known 
to have population based specificity therefore data 
from Pakistan has critical implications for implementa-
tion of appropriate treatment policy and development 
of elimination strategy. Molecular surveillance can pro-
vide a framework to rapidly monitor for the emergence 
or importation of resistance alleles.
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